Home › InterMune drug may offer big upside to Roche if aimed at liver
 

Keywords :   


InterMune drug may offer big upside to Roche if aimed at liver

2014-08-28 06:40:43| Biotech - Topix.net

Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

Tags: big offer drug aimed

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.05Beef Australia signs MOU with Canadian Western Agribition
08.05Sheboygan Paint Company Announces Promotion
08.05Space-age farm technology wins Beef2024 pitching contest
08.05American Cleaning Institutes Mid-Year Meeting is June 10-12
08.05Procter & Gamble Recognizes Key Suppliers
08.05Q1 2024 Net Revenue Up 28% for Oddity
08.05INX issues 2023 Sustainability Report
08.05Precision Textiles Elevates Mattress Safety and Comfort
More »